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Abstract: Eisenmenger syndrome is the most severe form of pulmonary arterial hypertension and arises on the basis of 
congenital heart disease with a systemic-to-pulmonary shunt. Due to the chronic slow progressive hypoxemia with central 
cyanosis, adult patients with the Eisenmenger syndrome suffer from a complex and multisystemic disorder including co-
agulation disorders (bleeding complications and paradoxical embolisms), renal dysfunction, hypertrophic osteoarthropa-
thy, heart failure, reduced quality of life and premature death. 
For a long time, therapy has been limited to symptomatic options or lung or combined heart-lung transplantation. As new 
selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arte-
rial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deteriora-
tion also in Eisenmenger patients. Unfortunately, data in Eisenmenger patients suffer from small patient numbers and a 
lack of randomized controlled studies. 
To optimize the quality of life and the outcome, referral of Eisenmenger patients to spezialized centers is required. In such 
centers, specific interdisciplinary management strategies of physicians specialized on congenital heart diseases and PAH 
should be warranted.  
This medical update emphasizes the current diagnostic and therapeutic options for Eisenmenger patients with particularly 
focussing on the medical treatment and corresponding study results. 
Keywords: Cardiovascular diseases, adult congenital heart defects, pulmonary hypertension, Eisenmenger syndrome, follow-
up studies, Competence Network for Congenital Heart Defects. 
1. MEDICAL MANAGEMENT - STUDY RESULTS 
  Timing of treatment in Eisenmenger patients is a sensi-
tive issue, particularly in stable patients. There exist no   
studies or guidelines on this subject. Especially for the stable 
patient, the “noli-me-tangere” ruling the treatment strategies 
for Eisenmenger patients still holds -at least to some extend- 
with respect to the delicate balance of the many variables, in 
spite of the available specific pulmonary vasodilators. On the 
other hand, treatment may indeed appear indicated because 
of reduced exercise tolerance, increasing cyanosis, or in-
creasing signs of heart failure [1].  
  However, it has to be kept in mind, that reduction of right 
ventricular afterload by pulmonary vasodilators is impossible 
in univentricular function. In other subtypes of congenital 
heart defects with Eisenmenger reaction (ER), the effect of  
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these drugs may be more pronounced on the systemic vascu-
lature, leading to systemic vasodilatation and, consecutively, 
in increased cyanosis. If indeed the pulmonary vascular sys-
tem preferentially vasodilates, the increased pulmonary 
blood flow may cause left heart failure and pulmonary 
edema. 
1.1. Anticoagulation 
  Systemic anticoagulation in patients with Eisenmenger 
syndrome (ES), remains controversial as randomized con-
trolled data are lacking [2]. Eisenmenger patients suffer from 
multivarious haemostatic abnormalities. On the one hand, ES 
is associated with a variety of procoagulant biochemical ab-
errations [3]. Thromboembolic events in the pulmonary cir-
culation occur in approximately 20% of these patients [4]. 
Therefore, anticoagulation seems logical for the prevention 
and treatment of thrombosis [5]. 
  Otherwise, Eisenmenger patients are at increased risk of 
fatal and life threatening bleeding complications, particularly 
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tion factors and abnormal fibrinolysis, there is thrombocy-
topenia with platelet malfunction.  
  Moreover, it is difficult to assess the optimal level of 
anticoagulation by routine laboratory tests (see below). So 
far, systemic anticoagulation and the use of platelet aggrega-
tion inhibitors is still not generally recommended in Eisen-
menger patients. 
1.2. Long-Term Oxygen-Therapy 
  The use of long-term oxygen supplementation in adult 
patients with ES is controversial. There are few data and 
only one published study with a prospective controlled de-
sign [6]. Although some patients (e.g. with intense hypoxe-
mia, dyspnea at rest and loss of vital capacity) might subjec-
tively benefit from oxygen supplementation, the risk and 
side-effects of this therapy (e.g. desiccation of nasal mucosa, 
epistaxis, sleep disturbance, etc.) should be taken into ac-
count. In addition, the above-mentioned trial [6] showed no 
impact of nocturnal oxygen therapy on exercise capacity, 
natural history and survival of the patients within a follow up 
period of 2 years.  
  According to the guidelines, supplemental oxygen is a 
general recommendation for PAH patients. The routine use 
of supplemental oxygen at home is not recommended for 
Eisenmenger patients, the use should be at the treating phy-
sician’s discretion. 
1.3. Nitric Oxide (NO) 
  Nitric oxide (NO) is a potent and selective pulmonary 
arteriolar vasodilator produced in endothelial cells [7]. It has 
a crucial function in regulating basal vascular resistance and 
may also affect platelets and vascular endothelial remode-
ling. Studies have shown inhaled NO to reduce pulmonary 
vascular resistance with minimal systemic effects in patients 
with ES and acute pulmonary hypertensive states of other 
etiologies [8, 9]. Amongst these, beneficial hemodynamic 
effects have been anecdotally described in children with ES 
[10]. 
  Due to the need of continuous inhalation, NO does not 
play any role in the long-term therapy and therefore only rare 
patients have been treated chronically. However, NO has an 
important role in the acute post-operative therapy. In addi-
tion, NO is established for the assessment of pulmonary vas-
cular reactivity to identify patients with advanced pulmonary 
hypertension and ES, who could benefit from sustained 
vasodilator treatment [11]. 
1.4. Calcium channel blockers (CCBs) 
  The use of high doses of oral calcium channel blockers in 
pulmonary arterial hypertension remains very limited. There 
is a lack of randomized controlled trials and the available 
data are restricted to patients with iPAH.  
  Even though favorable clinical and prognostic effects of 
high doses of CCB drugs have been suggested [12], these 
effects were only demonstrable in patients with iPAH with 
an acute response to vasodilator testing (“responders”) [13, 
14]. Hence, merely a minority subgroup of patients appears 
to benefit from this therapy. By contrast, CCB use in associ-
ated forms of PAH has been discouraged, particularly in pa-
tients who do not fulfill the criteria of hemodynamic re-
sponders, e.g. Eisenmenger patients [15]. 
  As the effects of CCB are not restricted to the pulmonary 
circulation, vasodilator therapy with CCBs could even cause 
complications. In Eisenmenger patients, systemic vascular 
resistance could be lowered more than pulmonary vascular 
resistance, thus increasing the right-to-left shunt with wors-
ening cyanosis and hypotension. For this reason, empiric 
CCB therapy in adult Eisenmenger patients is not recom-
mended [15].  
1.5. Endothelin-1 (ET-1) Receptor Antagonists 
  ET-1 is a powerful vasoconstrictor with elevated concen-
trations in the plasma and lung tissue of patients with PAH. 
It plays a key role in the pathogenesis of PAH including in 
vitro effects on proliferation, fibrosis and inflammation. As 
increased ET-1 plasma levels have been correlated with the 
severity and prognosis of PAH [16], the ET-1 pathway rep-
resents an important treatment target. 
Bosentan 
  Bosentan is a non-selective endothelin receptor antago-
nist with dual activity on both ETA and ETB receptors and 
thus completely blocking the activity of ET-1. It is the first 
oral drug of this medical category, which has been approved 
by the FDA and EMEA in 2002 as orphan-drug for the 
treatment of pulmonary hypertension, and currently also for 
mildly symptomatic patients [17]. Furthermore, since July 
2009 Bosentan is the only approved drug for the treatment of 
PAH in children, as there is a paediatric formulation ap-
proved for children with an age of at least 2 years [18, 19]. 
  Particularly for the treatment of Eisenmenger patients, 
several case series and uncontrolled studies have been pub-
lished, consistently demonstrating an improvement in exer-
cise capacity and hemodynamics with bosentan treatment 
[20-23].  
  BREATHE-5 was designed as the first randomized, pla-
cebo-controlled and double-blind trial exclusively enrolling 
Eisenmenger patients. After a treatment period of 16 weeks 
receiving bosentan, patients showed a significant improve-
ment in hemodynamics and 6 minute walking distance (6 
MWD), without adversely affecting systemic arterial oxygen 
saturation [24]. In the BREATHE-5 open-label extension 
study, improvement in exercise capacity was maintained up 
to 40 weeks [25]. So far, the results of this follow-up were 
confirmed in two prospective, uncontrolled and open-label 
studies, which demonstrated an initial persistent improve-
ment of objective exercise capacity, but a decline after one 
year [26] with reduction to baseline levels after two years 
[27]. In children, deterioration seemed to be more progres-
sive, whereas in adult patients with the ES, the improvement 
appeared to last longer. However, these data have to be 
evaluated carefully due to the limited long-term experience, 
small subject groups and uncontrolled trial designs. In addi-
tion, natural progression of the disease cannot be distin-
guished from a possible tachyphylaxis.  
  Overall, bosentan related side effects include dose-
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systemic hypotension. Bosentan may also interfere with the 
action of hormonal contraceptives. 
  In summary, based on the BREATHE-5 study as well as 
clinical evidence, bosentan seems to be safe and effective in 
PAH related to CHD, showing improvement in hemody-
namic parameters, exercise capacity and functional class. 
Further experiences with bosentan in another large cohort of 
Eisenmenger patients, conducted by the German Compe-
tence Network for Congenital Heart Defects, are expected in 
the near future. Bosentan is currently approved for the treat-
ment of severe PAH related to the ES.  
Sitaxsentan 
  Sitaxsentan is a potent and highly selective ETA receptor 
antagonist with a distinctive oral bioavailability and a half-
life of up to 7 hours, allowing effective once daily oral dos-
ing. Since October 2006, sitaxsentan is the first ETA receptor 
antagonist approved for the treatment of PAH. There are few 
randomized-controlled studies (Table 1), demonstrating im-
provements in exercise capacity, hemodynamic parameters, 
WHO functional class and clinical events in patients with 
PAH of different etiologies [28, 29]. Similar to other phar-
maceutical agents, the above-mentioned trials of sitaxsentan 
were predominantly focused on iPAH, while only a minority 
of patients suffered from PAH associated with CHD. Avail-
able data show that sitaxsentan has a lower incidence of he-
patic toxicity than bosentan, but affects the metabolism of 
Warfarin. 
  First long-term-results of a one year prospective, obser-
vational and open-label study have recently been published, 
suggesting sitaxsentan therapy to be safe and efficacious for 
patients with PAH. In an uncontrolled study arm, there was a 
suggestion that patients treated with sitaxsentan demon-
strated a longer time to clinical worsening than those in the 
bosentan group [30]. Unfortunately, there was no subanalysis 
of the data for the various subgroups of PAH, such as PAH 
related to CHD. Therefore no conclusion can be drawn con-
cerning Eisenmenger patients. 
Table 1.  Controlled Clinical Trials with Entothelin-1 Receptor Antagonists in Patients with PAH. (Table Adapted from Galie [33]) 
BREATHE-5 STRIDE-1  STRIDE-2  ARIES-1  ARIES-2 
Trial 
Galie Circulation 2006  Barst AJRCCM 2004  Barst JACC 2006  Galie Circulation 2008  Galie Circulation 2008 
Patients treated [n]  54 178  245  201  192 
Thereof PAH related 
to CHD 
100% 24%  11%  None  None 
Drug / Route  Bosentan p.o.  Sitaxsentan p.o.  Sitaxsentan p.o.  Ambrisentan p.o.  Ambrisentan p.o. 
Duration [weeks]  16 12  18  12  12 
Primary Endpoints  SpO2 Peak  VO2  6 MWD  6 MWD  6 MWD 
WHO Functional 
Class [%] 
              
 I  --- ---  ---  2.5  1.6 
 II  --- 33  37  32.3  44.8 
 III  100 66  59  58.2  51.6 
 IV  --- 1  4  7  2 
Treatment Effects 
 6 MWD [m] 
 
+ 53.1 (p=0.008) 
 
+ 35** (p<0.01) 
 
+ 31.4** (p=0.03)  + 51
# (p<0.001)  + 59
## (p<0.001) 
 Peak VO2  N/A +3,1%*  (p<0.01)  N/A  N/A  N/A 
 Hemodynamics  Improved Improved  N/A  N/A  N/A 
 WHO Functional 
Class 
35% improved  Improved (p<0.02)  Improved** 
(p=0.04) 
Improved (p=0.03)  NS 
Time to clinical  
worsening 
N/A  No significant differ-
ences between treat-
ment groups (100 mg 
vs. 300 mg) 
Trended toward an 
increase** 
NS p<0.001 
    * Sitaxsentan  
300 mg QD 
** Sitaxsentan  
100 mg QD 
# Ambrisentan  
10 mg QD 
## Ambrisentan  
5 mg QD 
Abbreviations: 6 MWD; 6 minute walking distance, Peak VO2; peak exercise oxygen uptake, SpO2; systemic pulse oxymetry, N/A; not applicable, NS; not significant, QD; once 
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  The experience with sitaxsentan specifically in Eisen-
menger patients remains limited. Currently, there are few 
anecdotal reports and no randomized trials. Only Rosen-
zweig [31] reported on a retrospective data analysis of sitax-
sentan treatment in 14 Eisenmenger patients. After a follow-
up period of up to 13 months, treatment appeared to be safe 
without a significant decrease in oxygen saturation. There 
was an improvement in hemodynamics and pulmonary to 
systemic vascular resistance ratio suggesting pulmonary se-
lectivity. 6 MWD improved, but this was not statistically 
significant. Limited data underscore the need for further 
studies in patients with the ES. 
Ambrisentan 
  Ambrisentan, another selective ETA receptor antagonist, 
has recently been approved for the treatment of PAH in 
WHO class II and III. ARIES-1 and ARIES-2 [32] (Table 1) 
demonstrated beneficial effects on exercise capacity (6 
MWD), WHO class and time to clinical worsening. Regret-
tably, no patients with PAH related to CHD were included in 
the trials and currently there are no further data available for 
Ambrisentan treatment in such patients. Therefore, no con-
clusion can be drawn concerning the effect of Ambrisentan 
in patients with ES. 
1.6. Phosphodiesterase-5 (PDE-5) inhibitors 
  Over the last years, PDE-5 inhibitors have been approved 
for the treatment of erectile dysfunction. As Type 5 PDE 
receptors are located predominantly in the penile and pulmo-
nary vasculature, PDE-5 inhibitors are a potential group of 
medications for the treatment of pulmonary arterial hyper-
tension. Currently, there are three different PDE-5 inhibitors, 
which have been studied in patients with PAH (Table 2).  
 
Table 2.  PDE-5 Inhibitors in Patients with PAH [34] 
 Sildenafil  Vardenafil  Tadalafil 
T max [min]  60  40 - 45  75- 90 
T 1/2 [h]  ~ 3,5  ~ 3,5  17,5 
PVR/SVR  Decrease ---  Decrease 
paO2  significant improvement  ---  --- 
Abbreviations: T max; time to peak hemodynamic effects, T ; mean half-life, 
PVR/SVR; pulmonary to systemic vascular resistance ratio, paO2; arterial oxygenation 
 
Table 3.  Controlled Clinical Trials with Prostacyclin Analogs in Patients with PAH. (Table Adapted from Galie [33]) 
Treprostinil ALPHABET  Beraprost-LT  AIR 
Trial 
Simonneau AJRCCM 2002  Galie JACC 2002 Barst  JACC 2003  Olschewski N Engl J Med 2002 
Patients [n]  469 130 116  203 
Thereof PAH related to 
CHD 
23% 18% 16%  None 
Drug / Route  Treprostinil s.c.  Beraprost p.o.  Beraprost p.o.  Iloprost inh. 
Duration [months]  3 3 12  3 
Primary Endpoints  6 MWD  6 MWD  Disease progression  6 MWD 
         Peak VO2  WHO Functional Class 
WHO Functional Class [%]             
 I  --- --- ---  --- 
 II  11 49 53  59 
 III  82 51 47  41 
 IV  7 ---  ---  --- 
Treatment Effects             
 6 MWD [m]  + 16 (p=0.006)  + 25 (p=0.036)  + 23 (p=0.18)  + 36 (p=0.06) 
 Peak VO2  N/A  N/A  Trend to increase (NS)  N/A 
 Hemodynamics  Improved  No Change  No Change  Improved 
 WHO Functional Class  N/A NS  58% unchanged 
(p=0.155) 
65% unchanged 
Time to clinical worsening  N/A N/A N/A  N/A 
Abbreviations: 6 MWD; 6 minute walking distance, Peak VO2; peak exercise oxygen uptake, N/A; not applicable, NS; not significant 360    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Mebus et al. 
Sildenafil and tadalafil
1 have shown beneficial effects on 
pulmonary selectivity and arterial oxygenation. 
  SUPER-1, the pivotal study of Sildenafil [35], was the 
first large prospective multicenter blinded and controlled 
study demonstrating an improvement in exercise capacity, as 
assessed according to the six-minute walking test, functional 
class and hemodynamics in PAH patients. Therefore a treat-
ment dose of 20 mg three times per day (TID) has been ap-
proved by the FDA and EMEA. Unfortunately, there is no 
sufficient experience for long-term-treatment. In those pa-
tients treated long-term, higher doses were used.  
  Similar to other vasodilators, sildenafil showed promis-
ing effects in patients with iPAH. Recently, favorable effects 
have been reported in patients with the ES. However, so far 
there are only a number of individual cases, several case 
series [36], observational studies and few randomized pla-
cebo-controlled trials [37] with increasing evidence for   
sildenafil in Eisenmenger patients.  
  In summary, preliminary results have demonstrated that 
sildenafil is safe and improved symptomatic status, func-
tional class, exercise capacity (6 MWD and exercise dura-
tion) and pulmonary hemodynamic parameters in patients 
with severe pulmonary hypertension related to the ES [38-
40]. As these data are based on relatively small subject 
groups, appropriate studies with larger cohorts are necessary, 
and are currently being conducted by the German Compe-
tence Network for Congenital Heart Defects. 
 Tadalafil is another PDE-5 inhibitor reported to affect 
PAH in patients with the ES in an observational study. In 
one study from India, oxygen saturation and the mean func-
tional class improved after a 12-weeks treatment with tada-
lafil in selected symptomatic Eisenmenger patients [41]. At 
this time, the limited available data show tadalafil to be safe 
and effective in these patients, even though further investiga-
tions are required.  
1.7. Prostacyclin and Prostacyclin Analogs 
  Prostanoids can be administered by continuously intrave-
nous or subcutaneous infusion, by inhalation and orally. Due 
to their active profile with vasodilatory, antiproliferative, 
anti-inflammatory and anticoagulant effects, they are suitable 
drugs for the treatment of PAH (Table 3). In current treat-
ment algorithms for patients with WHO Functional Class III 
and IV, prostacyclin analogs are indicated particularly in 
patients with right heart failure.  
Epoprostenol 
  Prostacyclin is a potent endogenous vasodilator produced 
in the vascular endothelium. Epoprostenol was the first syn-
thetic prostacyclin analog, which became standard therapy of 
severe PAH in many countries. Due to a short half-life of a 
few minutes, continuous i.v.-infusion of epoprostenol is re-
quired, which exposes patients to significant side-effects and 
associated risks. Epoprostenol is well studied in patients with 
                                                         
1 Galie N, Brundage H, Ghofrani A, Oudiz RJ, Simonneau G, Beardsworth A, Chan M, 
Barst RJ. Tadalafil therapy in pulmonary arterial hypertension: results of a randomized, 
double-blind, placebo-controlled, phase III study. European Heart Journal 2008; 29 
(Abstract Supplement): 519 
iPAH, and randomized controlled trials have shown im-
provements in exercise capacity, quality of life and hemody-
namics [33, 42]. In patients with PAH caused by congenital 
cardiac lesions in whom conventional therapy has failed, 
long-term prostacyclin therapy has shown amelioration in 
hemodynamics and quality of life following one year of 
treatment [43, 44], even though there were serious adverse 
events reported, including cerebrovascular accidents. An-
other case series studied i.v.-epoprostenol in Eisenmenger 
patients, showing improved oxygenation and 6 MWD [45]. 
Unfortunately, the data are limited and there is a lack of ran-
domized controlled trials in patients with ES. Although Eis-
enmenger patients might also benefit from this treatment 
option with intravenous epoprostenol, there exist limited data 
on the efficacy and safety [43]. 
Iloprost 
  Intravenous iloprost is a very stable prostacyclin analog 
and therefore an alternative to i.v.-prostacyclin. Inhaled ilo-
prost has been studied extensively and it has been assumed 
that it is pulmonary selective, thus minimizing systemic side 
effects [46]. With a serum half-life of up to 25 minutes after 
inhalations, inhaled iloprost has to be administered 6-8 times 
per day. One randomized controlled trial with a 12-weeks 
treatment period with inhaled iloprost showed beneficial 
effects in terms of hemodynamics, exercise capacity, symp-
toms and clinical events [47] in patients with iPAH. So far, 
the efficacy in adult Eisenmenger patients has not yet been 
studied. 
Treprostinil 
  Treprostinil is a stable prostacyclin analog with a half-
life of three hours, currently available for subcutaneous and 
intravenous application. The effects of its continuous subcu-
taneous administration were studied in a large randomized 
controlled trial with patients suffering from iPAH (58%), 
PAH related to connective tissue disease (19%) and PAH 
caused by CHD (24%). There were beneficial effects on ex-
ercise capacity, hemodynamics and clinical events [48], but 
notably a high frequency of site pain limiting subcutaneous 
administration. For intravenous application, only few data 
exist with minuscule evidence for PAH in relation to con-
genital cardiac lesions [49]. Long-term use of treprostinil has 
resulted in similar survival benefits as i.v. epoprostenol [50].  
Beraprost 
  Beraprost is the first orally active prostacyclin analog that 
is approved for treatment of iPAH only in Japan. After oral 
administration, peak concentrations are reached after 30 
minutes.  
  There are two randomized controlled trials with beraprost 
and a relatively large trial size of 130 and 116 patients, suf-
fering from iPAH and PAH associated with connective tissue 
disease and CHD, respectively. In the first trial, patients 
were randomized to receive the maximal tolerated dose of 
beraprost or placebo for 12 weeks [51]. Subgroup data 
analysis demonstrated that beraprost improved exercise ca-
pacity particularly in patients with iPAH, while those with 
associated conditions showed no significant changes. 
Moreover, there were no relevant beneficial effects in car-
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The second trial studied the long-term effects of beraprost 
treatment up to one year [52]. During earlier phases of treat-
ment, data suggest less disease progression persisting up to 6 
months, but after one year, there was no longer any differ-
ence between the beraprost and the placebo groups. There-
fore, beraprost does not play a crucial role in the treatment of 
PAH related to congenital cardiac lesions and ES.  
1.8. Combination Therapy 
  Combination of various drugs may have synergistic ef-
fects through interaction of different pathobiological path-
ways [53-56]. Data are limited, but combination therapy may 
be considered for symptomatic patients who failed to im-
prove with first-line, monodrug treatment. Several small 
trials with limited recruiting numbers are under way, but so 
far there are only anecdotal reports and different single-
center experiences of Eisenmenger patients treated with a 
combination of specific anti-pulmonary hypertensive agents 
[57, 58]. It could be expected that a combination therapy as 
goal oriented treatment in Eisenmenger patients may be a 
more beneficial standard therapy in the future, but caution 
should be advised to unknown interactions of the agents with 
regard to potential toxicity. Currently, controlled data justify-
ing the use of combination therapy in ES patients are lack-
ing. 
1.9. Outlook for the Future 
  Future studies need to define valid and practical end-
points that are customized to ES patients. While what we 
learn and achieve here may serve as a model for pulmonary 
vascular disease in CHD in general. It will be an important 
question, whether drugs affecting remodeling processes will 
be usable.  
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